What began as a casual conversation among friends has evolved into a significant breakthrough in South Africa’s biotechnology sector, aiming to make lab-grown meat more affordable. Immobazyme, a startup founded by three Stellenbosch University graduates, is collaborating with the Council for Scientific and Industrial Research (CSIR) to produce a vital ingredient essential for cultivated meat production, a development poised to lower costs in a field that is still navigating the challenges of scalability.
Founding the Vision
Immobazyme was established by Dominic Nicholas, Ethan Hunter, and Nick Enslin, whose paths crossed during their honors year at Stellenbosch University. Their shared interest in biotechnology blossomed during their postgraduate studies, where they engaged in discussions on enhancing the accessibility of enzyme-based technologies.
The team is now focused on producing fibroblast growth factor 2 (FGF-2), a protein critical for cultivating animal cells in lab-based meat production. According to Enslin, the company’s chief commercial officer, the process involves taking a single cell from an animal—be it a cow, fish, or chicken—and multiplying it in the lab until it forms a viable food product.
Addressing Cost Challenges
Despite the innovative potential of cultivated meat, Enslin highlights that the industry is highly cost-sensitive, primarily due to the expensive growth factors like FGF-2. He notes that approximately 90% of the costs associated with lab-grown meat arise from these growth factors.
The local cultivated meat sector in South Africa remains relatively nascent, with limited active companies. Notable players include Mzansi Meat, which has rebranded as Newform Foods and relocated its headquarters to the UK. This scenario presents a unique challenge, as the scope for impactful innovation is currently constrained.
Fostering Local Innovation
Enslin expresses optimism that local production of biotech ingredients could foster the growth of a future sector. He envisions that upcoming companies in the realm of lab-grown meats can collaborate with local ingredient manufacturers to secure affordable growth factors, thus stimulating a wave of new entrepreneurship in the biotech space.
Breakthrough Partnership with CSIR
The collaboration between Immobazyme and CSIR marks a pivotal moment in scaling up FGF-2 production. Utilizing genetically modified bacteria and large bioreactors, the partnership aims to enhance production capabilities. Dr. Veshara Ramdas, a biotechnology expert at CSIR, emphasizes that this collaboration has allowed for the demonstration of a process for producing the growth factor at a 50-liter bioreactor scale for the first time in South Africa.
This achievement not only supports the local biotechnology industry but also sets the stage for producing other essential growth-related proteins, broadening the scope for future innovations.
Safety and Regulation Standards
As the company develops its processes, Enslin emphasizes the importance of adhering to established manufacturing standards. The production process is designed to comply with safety regulations, ensuring that the final food products undergo rigorous assessments by local authorities. The approval process assesses various factors, including safety certifications and dietary compliance, such as halal and kosher standards.
Support and Growth
The project has received backing from the Department of Science, Technology, and Innovation, as well as the Technology Innovation Agency, through the Biomanufacturing Industry Development Programme. Enslin acknowledges the significance of this support, stating that the collaboration has been vital to the company’s growth.
“The Biomanufacturing Industry Development Centre (BIDC) is a world-class facility,” he notes, highlighting not only the advanced equipment but also the collaborative spirit that has fueled the flow of ideas and innovation.
Future Aspirations
Looking ahead, Immobazyme plans to expand its production capabilities and continue developing additional proteins. Enslin reflects on the journey, noting that the partnership has yielded commercially viable products, marking a significant milestone for the company.
In conclusion, Immobazyme’s strides in biotechnology not only aim to reduce the costs of cultivated meat but also hold the potential to revolutionize the local industry. By fostering collaboration and innovation, the startup is paving the way for a more sustainable and accessible future for lab-grown meat.
- Local biotech ingredient production can stimulate industry growth.
- Collaboration with CSIR enables scalable production techniques.
- Stringent safety and regulatory measures ensure product integrity.
- Immobazyme’s success could inspire new biotech entrepreneurship.
- The partnership showcases the importance of idea exchange in innovation.
Read more → www.timeslive.co.za